Nuformix plc (LON:NFX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2650
+0.0150 (6.00%)
Feb 12, 2026, 4:05 PM GMT
Market Cap5.59M +378.5%
Revenue (ttm)n/a
Net Income-652.59K
EPS-0.00
Shares Out2.11B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,919,384
Average Volume42,915,115
Open0.2733
Previous Close0.2500
Day's Range0.2500 - 0.2800
52-Week Range0.0695 - 0.5550
Beta1.30
RSI55.58
Earnings DateJan 30, 2026

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP0... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol NFX
Full Company Profile

Financial Performance

Financial Statements